| NCT07187973 | A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) | NOT_YET_RECRUITING | PHASE1 | 2025-10 | 2027-10 | 2027-06 |
| NCT06985147 | A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | RECRUITING | PHASE2 | 2025-08-12 | 2029-02 | 2027-02 |
| NCT06910358 | Study of Bitopertin in Participants With EPP or XLP (APOLLO) | RECRUITING | PHASE3 | 2025-04-04 | 2026-11 | 2026-10 |
| NCT06050915 | A Study of DISC-3405 in Healthy Volunteers | COMPLETED | PHASE1 | 2023-10-03 | 2024-07-09 | 2024-07-09 |
| NCT05883748 | Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP | ENROLLING_BY_INVITATION | PHASE2, PHASE3 | 2023-08-31 | 2028-06 | 2028-06 |
| NCT05745883 | Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-04-04 | 2026-05 | 2025-09 |
| NCT05308472 | Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants with EPP | COMPLETED | PHASE2 | 2022-10-31 | 2024-08-23 | 2024-02-20 |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | RECRUITING | PHASE1, PHASE2 | 2022-06-06 | 2026-09 | 2026-09 |
| NCT04999527 | Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects | COMPLETED | PHASE1 | 2021-08-10 | 2022-06-30 | 2022-06-30 |